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Preclinical studies of enzyme-replacement therapy for Fabry disease (deficient a-galactosidase A [a-Gal A] activity)
were performed in a-Gal A–deficient mice. The pharmacokinetics and biodistributions were determined for four
recombinant human a-Gal A glycoforms, which differed in sialic acid and mannose-6-phosphate content. The
plasma half-lives of the glycoforms were ∼2–5 min, with the more sialylated glycoforms circulating longer. After
intravenous doses of 1 or 10 mg/kg body weight were administered, each glycoform was primarily recovered in
the liver, with detectable activity in other tissues but not in the brain. Normal or greater activity levels were
reconstituted in various tissues after repeated doses (10 mg/kg every other day for eight doses) of the highly sialylated
AGA-1 glycoform; 4 d later, enzyme activity was retained in the liver and spleen at levels that were, respectively,
30% and 10% of that recovered 1 h postinjection. Importantly, the globotriaosylceramide (GL-3) substrate was
depleted in various tissues and plasma in a dose-dependent manner. A single or repeated doses (every 48 h for
eight doses) of AGA-1 at 0.3–10.0 mg/kg cleared hepatic GL-3, whereas higher doses were required for depletion
of GL-3 in other tissues. After a single dose of 3 mg/kg, hepatic GL-3 was cleared for 4 wk, whereas cardiac
and splenic GL-3 reaccumulated at 3 wk to ∼30% and ∼10% of pretreatment levels, respectively. Ultrastructural
studies demonstrated reduced GL-3 storage posttreatment. These preclinical animal studies demonstrate the dose-
dependent clearance of tissue and plasma GL-3 by administered a-Gal A, thereby providing the in vivo ratio-
nale—and the critical pharmacokinetic and pharmacodynamic data—for the design of enzyme-replacement trials
in patients with Fabry disease.
Introduction
Fabry disease (MIM 301500) is an X-linked inborn error
of glycosphingolipid catabolism and results from the de-
ficient activity of the lysosomal exoglycohydrolase, a-
galactosidase A (a-Gal A) (Desnick et al. 1995, 2001).
Classically affected males, who have little, if any, a-Gal
A activity, progressively accumulate the neutral glyco-
sphingolipid, globotriaosylceramide (GL-3), primarily in
the lysosomes of vascular endothelial cells of the heart,
liver, kidneys, skin, and brain. Onset of the classic dis-
ease phenotype occurs during childhood or adolescence
and is characterized by severe acroparesthesias, angio-
keratoma, corneal and lenticular opacities, and hypohi-
drosis. With advancing age, vascular disease of the heart,
kidneys, and brain leads to early demise during the 4th
or 5th decade of life (Colombi et al. 1967).
Current treatment for Fabry disease is nonspecific and
supportive, primarily limited to symptomatic manage-
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ment of the excruciating pain and the complications of
renal, cardiac, and/or cerebrovascular disease. Attempts
to deplete the accumulated substrate and to alter dis-
ease progression by kidney transplantation (Maizel et
al. 1981), phlebotomy (Beutler et al. 1983), or plas-
mapheresis (Kolodny et al. 1981), have not been not
successful. Therefore, Fabry disease is an attractive
candidate for enzyme-replacement therapy, particular-
ly because classically affected patients lack neural in-
volvement.
Initial efforts to replace the defective enzyme in clas-
sically affected males involved the administration of sin-
gle doses of either normal plasma containing active,
highly-sialylated a-Gal A (Bishop et al. 1981; Mapes et
al. 1970) or partially purified enzyme from human pla-
centa (Brady et al. 1973). The plasma glycoform, which
was highly sialylated, was retained in the circulation
longer (half-life [T½] ∼90 min) than was the placental
glycoform (10 min), whose oligosaccharides were par-
tially processed in placental lysosomes. Importantly,
these single-dose studies indicated that intravenously in-
fused enzyme from either source could decrease the level
of accumulated plasma GL-3. A subsequent pilot study
compared, over a 3-mo period, the effectiveness and
safety of six doses (∼0.05 mg/kg) of human a-Gal A
glycoforms from splenic lysosomes or plasma (Desnick
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Figure 1 IEF gel of the four a-Gal A glycoforms used in the
present study. The highly sialylated glycoforms, AGA-1 and AGA-3,
had the lowest pI values.
et al. 1979). The well-tolerated enzyme infusions dem-
onstrated that the splenic-derived enzyme was cleared
rapidly from the circulation (T½ ∼10 min) and tran-
siently decreased the circulating GL-3 concentration (!1
h), whereas the more highly sialylated plasma-derived
enzyme had a slower plasma clearance (T½ ∼70 min)
and effected a longer and more profound depletion of
the circulating GL-3 (136 h). It is noteworthy that two
doses of the plasma-derived enzyme, one infused at 0
h and the other infused at 48 h, reduced the plasma
substrate level to within the normal range (Desnick et
al. 1980). These studies demonstrated the feasibility of
enzyme-replacement therapy for Fabry disease; how-
ever, the rate-limiting obstacles to clinical trials were the
inability to produce sufficient amounts of purified nor-
mal enzyme and the absence of an animal model to
evaluate the pharmacokinetics, biodistribution, and
pharmacodynamics required for the design of clinical
trials.
These obstacles were overcome by the isolation of the
human a-Gal A cDNA (Bishop et al. 1986) and its high
level expression in Chinese hamster ovary (CHO) cells
(Ioannou et al. 1992), which provided a source of se-
lectively secreted human recombinant enzyme that was
sialylated and that had mannose-6-phosphate (M6P)
residues for lysosomal targeting. In addition, the gen-
eration of an a-Gal A–knockout mouse model of Fabry
disease permitted the preclinical evaluation of enzyme
replacement (Wang et al. 1996). In this communication,
we report the pharmacokinetics, biodistribution, and
stability of various a-Gal A glycoforms after their in-
fusion into the a-Gal A–deficient mouse model of Fabry
disease. Use of a highly sialylated glycoform (i.e., AGA-
1) demonstrated, biochemically and morphologically,
the dose-dependent plasma and tissue clearance of ac-
cumulated GL-3. These animal-model studies provided
the “proof of concept” and critical preclinical infor-
mation for the design of clinical trials of a-Gal A re-
placement in patients with Fabry disease.
Material and Methods
Animal Model
a-Gal A–deficient mice were produced by homologous
recombination in 129/Sv embryonic stem (ES) cells, by
a replacement-type vector containing both the neomy-
cin-resistance gene, for positive selection, and the thy-
midine kinase gene, for negative selection (Wang et al.
1996). Affected mice were totally deficient in a-Gal A
activity and progressively accumulated GL-3 in both
plasma and the lysosomes of most tissues (in particular,
the liver, spleen, heart, skin, and kidneys). They had no
clinical disease phenotype and survived a normal labo-
ratory life span (∼2 years). Hemizygous affected males
were bred to homozygous affected females, thereby pro-
viding only affected offspring. For these studies, all mice
were affected adult males ∼5 mo old that weighed 20–30
g. Mice were provided standard mouse chow and water
ad libidum.
Production, Purification, and Characterization of the
Recombinant Human a-Gal A Glycoforms
Four human a-Gal A glycoforms were produced and
purified, in order to compare their pharmacokinetics,
biodistribution, and stability in a-Gal A–deficient mice.
Two glycoforms, designated “AGA-1” and “AGA-2,”
were produced by stable, amplified expression of the
normal human a-Gal A cDNA in DUKX B11 and DG44
CHO cells, respectively, as described elsewhere (Ioannou
et al. 1992). To produce glycoform AGA-3, CHODG44
cells overexpressing glycoformAGA-2were stably trans-
fected with a rat a-2,6-sialyltransferase cDNA gener-
ously provided by Dr. James Paulson (Los Angeles) (Wen
et al. 1992). Enzyme produced by this modified cell line
was highly sialylated, as shown by both its increased
mobility on isolectric focusing (IEF) gels (fig. 1) and its
binding to immobilized Sambucus nigra agglutinin (data
not shown), a lectin specfic for a-2,6-sialic acid residues
(Lee and Nathans 1988). Glycoform AGA-4 was con-
structed by site-specfic mutagenesis of the a-Gal A
cDNA, to alter the consensus N-glycosylation site at
N192 (asparagine to glutamine) and to delete one N-
linked high–mannose oligosaccharide chain per mono-
mer, thereby eliminating four M6P residues per active
homodimeric enzyme (Ioannou et al. 1998; Matsuura et
al. 1998). This construct was transiently overexpressed
in COS-1 cells (Desnick et al. 1995, 2001). All four
secreted glycoforms were purified by a-D-galactosyla-
mine chromatography (Bishop et al. 1981), were con-
centrated (10.5 mg/ml) in citrate-phosphate buffer (pH
6.0) containing 1 mg bovine serum albumin/ml, and
were stored at 4C.
Molecular weights and isoelectric points (pIs) were
estimated by SDS-PAGE and IEF, on the PhastSystem
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(% of Initial Activity)
pH 4.6 pH 7.4
AGA-1 Stable/DUKX B11 ∼56 3.9–4.7  6  100 50
AGA-2 Stable/DG44 ∼50 4.4–4.9  6  100 52
AGA-3 Stable/DG44 ∼55 4.0–4.6  6  94 49
AGA-4 Transient/COS-1 ∼52 4.2–4.6  2  83 33
a Based on IEF (fig. 1) and a-neuraminidase studies (data not shown).
b In vitro hydrolysis of GL-3, assessed by HPTLC analysis.
c At 37C, after incubation for 1 h.
Figure 2 Pharmacokinetics of a-Gal A glycoforms (1mg/kg).
Inset, Biostability of AGA-1 in the liver and spleen. Each value point
represents the mean  1 SD for three or four mice.
(Pharmacia), by use of precast 12.5% polyacrylamide
PhastGels and precast pH 4–6.5 gels, respectively, ac-
cording to the manufacturer’s recommendations. Sialy-
lation was assessed by a-neuraminidase digestion ac-
cording to the manufacturer’s recommendations (Boeh-
ringer-Mannheim), followed by IEF. Mannose-6-phos-
phorylation was assessed by incubation of cultured hu-
man Fabry fibroblasts with units (nmol/h) of45# 10
each glycoform, in both the presence and the absence of
5 mM M6P, to determine enzyme uptake by the M6P
receptor (data not shown).
Animal Injections and Specimen Collection
Individual mice were placed in an illuminated plex-
iglass restraining device, and the indicated dose of the
enzyme was injected into the tail vein, ∼0.1 ml during
∼3 s. Blood samples were obtained by either tail bleed
or retro-orbital eye bleed, by use of heparinized micro-
hematocrit tubes. Mice were anesthetized by intramus-
cular injection of 50 ml of a solution of 100mg ketamine/
ml (Sigma) and were perfused with 50 ml of 0.9% saline,
to remove heme, which interfered with the fluorometric
a-Gal A enzymatic assay. The liver, spleen, heart, lungs,
brain, kidneys, and dorsal and ventral skin biopsies from
shaved mice were obtained and were snap-frozen in liq-
uid nitrogen. Organs were stored at 20C prior to en-
zyme or GL-3 analyses.
Study Design
To compare the pharmacokinetics of the four a-Gal
A glycoforms, each was injected at a concentration of 1
mg/kg, and its plasma clearance rate was determined.
The biodistribution of 1 or 10 mg of the glycoforms/kg
of body weight was assessed in selected organs after the
mice were killed and perfused with saline, 1 h after in-
travenous administration of the glycoform. After a dose
of 1 mg/kg, the tissue stability of glycoform AGA-1 was
determined in the liver and spleen, at 24-h intervals over
4 d. To determine the biodistribution and/or effect that
the enzyme dose had on the tissue or plasma GL-3 levels,
0.3, 1.0, 3.0, or 10.0 mg of AGA-1/kg was injected as
either a single dose or eight doses, at 48-h intervals. The
mice were killed 24 h after the last injection, and the a-
Gal A activity and/or GL-3 levels were determined. All
reported values represent the mean in three to six mice
for each time point and dose, unless otherwise indicated.
Enzymatic Activity, Protein, and GL-3 Assays
To determine the a-Gal A activity in tissues, freshly
obtained or thawed tissue samples were placed in 50-
ml polypropylene tubes containing lysis buffer (27 mM
citric acid, 46 mM sodium phosphate dibasic, 0.15%
Triton X-100, pH 4.6) and were homogenized on ice by
use of a Tissue Tearor (Biospec Products) for 2 min (at
setting 3). Debris was pelleted by centrifugation at room
temperature, and the soluble fractions were assayed for
a-Gal A activity at 37C, by use of 5 mM 4-methylum-
belliferyl-a-D-galactopyranoside (or 4MU-a-Gal) con-
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Table 2
Mean Recovered Activity of Intravenously Administered Human a-Gal A Glycoforms in a-Gal A Deficient Mice
TISSUE
MEAN RECOVERED ACTIVITY OF GLYCOFORM [DOSE]a
(%)
AGA-1 [1.0 mg/kg] AGA-1 [10.0 mg/kg] AGA-2 [1.0 mg/kg] AGA-3 [1.0 mg/kg] AGA-4 [1.0 mg/kg]
Liver 94.5 93.5 94.8 94.7 95.3
Spleen 2.8 3.5 2.8 2.0 2.7
Kidneys 1.3 2.7 1.3 1.0 1.0
Heart ND .4 ND ND ND
Lungs ND .3 ND ND ND
Brain ND ND ND ND ND
NOTE.—Total activity recovered in the tissues listed was 25%–30% of administered dose.
a In at least three mice killed 1 h postinjection. ND p not detectable.
Table 3
Mean Activity after Repeated Intravenous Administration of AGA-1












Liver 16.8 1,160 #69.2
Spleen 39.2 44.7 #1.14
Kidneys 11.3 14.0 1.24
Heart 3.2 17.7 #5.40
Lungs 29.8 5.4 #.83
Brain 26.9 ND
a In at least three mice injected with 10 mg/kg every other day for
eight doses and killed after injection 8 on day 15. NDp not detectable.
taining 117 mM N-acetylgalactosamine at pH 4.6, as
described elsewhere (Bishop et al. 1980) (1 unit [U] of
a-Gal A activity p 1 nmol of substrate hydrolyzed/h).
Enzymatic activity was detectable in tissues at levels
10.01 U/mg. Protein concentrations were determined by
the fluorescamine method (Bohlen et al. 1973). GL-3
analysis and quantitation were performed according to
an enzyme-linked immunosorbent assay (ELISA) us-
ing the b-subunit of Escherichia coli verotoxin, which
specifically binds GL-3 (Zeidner et al. 1999). GL-3 con-
centrations were expressed as nanograms of GL-3 per
milligram of wet tissue. In addition, qualitative and semi-
quantitative analyses of tissue glycolipids were per-
formed by high-performance thin-layer chromatography
(HPTLC), as described elsewhere (Kupke and Zeugner
1978; Zeidner et al. 1999).
Morphological Studies
After mice were killed and perfused as described
above, tissues were removed and minced into 2-mm
cubes, which were immediately immersed in 0.2 M so-
dium cacodylate buffer, pH 7.4, containing 3% glutaral-
dehyde. Tissues were postfixed with 1% osmium te-
troxide buffered with sodium cacodylate, for 1 h; were
dehydrated in ethanol, through propylene oxide; and
were embedded in Embed 812 resin (Electron Micros-
copy Sciences). One-micron plastic sections were cut,
stained with methylene blue and azure II, and observed
by light microscopy, to choose representative areas for
ultrathin sectioning and examination by electron mi-
croscopy using a JEM 100CX electron-transmission mi-
croscope (Jeol).
Results
Characterization of the Human Recombinant a-Gal A
Glycoforms
Table 1 compares the physical and kinetic properties
of the four recombinant human a-Gal A secreted gly-
coforms. AGA-1 and AGA-2 were stably overexpressed
by different CHO cell lines (Ioannou et al. 1992) and
had similar specific activities toward the native glyco-
lipid and artificial fluorogenic substrates. These two gly-
coforms differed only in the degree of sialylation, with
both IEF migration (fig. 1) and a-neuraminidase diges-
tion (data not shown) showing AGA-1 as being more
highly sialylated. For comparison, the complete oligo-
saccharide structures on AGA-2 were determined (Mat-
suura et al. 1998). AGA-3, produced by stably intro-
ducing the rat a-2,6-sialyltransferase gene into the
AGA-2–overexpressing CHO line, had properties simi-
lar to those of AGA-2, except that it was more highly
sialylated and contained a-2,6-linked sialic acid residues,
which are not normally synthesized by CHO cells. AGA-
4 was designed, by site-specific mutagenesis, to eliminate
the high-mannose oligosaccharide chain from each a-
Gal A glycopeptide (Ioannou et al. 1998). The resultant
active homodimeric enzyme, overexpressed in COS-1
cells, had only two M6P residues (one on each hybrid
oligosaccharide chain at N215) and, at pH 7.4, was
somewhat less stable than AGA-1 (33% vs. 50%, re-
spectively, of initial activity at 37C).
Pharmacokinetics and Biodistribution of the a-Gal A
Glycoforms
After a single intravenous dose of 1 mg/kg, each a-
Gal A glycoform was cleared from the circulation of the
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a-Gal A–deficient mice in two phases—a rapid phase
with a plasma T½ of ∼2–5 min and a second, longer
phase (fig. 2). AGA-1 and AGA-3, the two most highly
sialylated glycoforms, had the longest T½ (∼3–5 min) for
the rapid-clearance phase and then circulated longer and
at higher levels (activity at 20min was∼10%and∼15%,
respectively, of the activity at 1 min). AGA-3, engineered
to have a-2,6-linked (as well as a-2,3-linked) sialic acid
residues, circulated the longest of all four glycoforms.
In contrast, the AGA-4 glycoform, in which the N192
glycosylation site was eliminated, was most rapidly
cleared from the circulation, with a T½ of ∼2 min, but
remained detectable for 120 min, at ∼10% of its activity
at 1 min.
The biodistribution of each glycoformwas determined
after a single injection of 1.0 mg/kg. For all four gly-
coforms, the total activity recovered, 1 h postinjection,
from the brain, heart, kidneys, liver, lungs, and spleen
was consistently 25%–39% (mean 29.3%; ) ofnp 14
the administered dose. Surprisingly, ∼95% of each gly-
coform was recovered in the liver (∼28% of adminis-
tered dose), and, for all four glycoforms, were similarly
taken up by the spleen and kidneys (∼2%–3% and ∼1%,
respectively, of recovered activity) (table 2). At this dose,
none of the glycoforms was detected in the heart, lungs,
or brain. On the basis of these remarkably similar find-
ings, the highly sialylated AGA-1 glycoformwas selected
for further studies.
Biodistribution and Stability of AGA-1
To determine the effect that an increased dose of AGA-
1 would have on the enzyme’s biodistribution, 10 mg
of AGA-1/kg was administered, and the a-Gal A activity
in various tissues was assessed 1 h postinjection. The
percentage of enzyme recovered in the liver decreased
slightly, reflecting the increased activity detected in the
spleen, in the heart, and, in particular, in the kidneys.
Also, a low level of a-Gal A activity was detected in the
lungs, but no activity crossed the blood-brain barrier,
even at this high dose.
The stability of AGA-1 activity in the liver and spleen
was determined after a dose of 1 mg/kg (fig. 2, inset).
The T½ of the enzyme activity in the liver and spleen
was ∼48 and ∼36 h, respectively. Notably, 96 h postin-
jection, the liver and spleen retained ∼30% and ∼20%
of the AGA-1 activity recovered at 1 h, respectively.
These findings indicated that the enzyme was active and
relatively stable after uptake, presumably in tissue
lysosomes.
To assess the role that reticuloendothelial mannose
receptors play in enzyme uptake, particularly by the liver
and spleen, mice were intravenously injected with ∼0.1
mg of yeast mannans/kg, 20 min prior to administration
of 0.5 mg of AGA-1/kg. The mannan-treated mice re-
tained 40% of the AGA-1 activity in the circulation 1
h postinjection, compared with !5% in untreated mice.
With mannan pretreatment, the percentage of a-Gal A
activity recovered in the kidneys 1 h after enzyme in-
jection increased from ∼1% to 10%. Thus, the distri-
bution of injected enzyme was altered by increasing the
dose or by blocking the mannose receptors on reticu-
loendothelial cells.
Repeated AGA-1 Dosing: Reconstitution of Tissue a-
Gal A Activity
To determine the levels of a-Gal A activity that could
be attained in various tissues, eight every-other-day
doses of AGA-1 (10 mg/kg) were injected, and the mice
were killed 24 h after the last dose, on day 15 (table 3).
As expected, the a-Gal A activity recovered in the liver
was markedly greater (∼70-fold), whereas the activity in
the heart was ∼5-fold greater, and the activities in the
spleen, kidneys, and lungs were near or slightly greater
than the respective wild-type activity. In contrast, no
activity was detected in the brain, even after repeated
high doses of enzyme.
Depletion of Tissue GL-3: Dependence on AGA-1
Dose
Tissue GL-3 concentrations were determined for 7 d
after a single intravenous injection of 0.3, 1.0, or 3.0
mg of AGA-1/kg (table 4). A single dose of 0.3 mg/kg
cleared 190% of the accumulated hepatic substrate, and
increased doses of 1.0 and 3.0 mg/kg completely cleared
the glycolipid (!1.0 ng/mg). The GL-3 clearances in the
spleen, heart, and kidneys also were dose dependent,
with a single dose of 3 mg/kg resulting in ∼90%, ∼65%,
and ∼37% clearance, respectively.
Accumulated Tissue GL-3 Cleared by Repeated AGA-1
Doses
The effect that repeated AGA-1 doses had on the de-
pletion of tissue GL-3 was determined 24 h after eight
every-other-day intravenous administrations of 0.3, 1.0,
3.0, or 10 mg of AGA-1/kg (table 5). All doses cleared
the accumulated GL-3 in the liver to nondetectable lev-
els. A dose-dependent depletion of accumulated GL-3
was observed in the heart, spleen, and kidneys. Doses
of 3 and 10 mg/kg reduced the GL-3 concentrations in
the heart and spleen to nondetectable levels, whereas
repeated doses of 10 mg/kg reduced the marked accu-
mulation in the kidneys to ∼40% of the untreated level.
These reductions were determined by ELISA of GL-3
and were confirmed by HPTLC analysis (data not
shown). It is noteworthy that only one of the two GL-
3 bands observed in the kidneys of untreated a-Gal
A–deficient mice was depleted in a dose-dependent man-
ner by the administered enzyme. To confirm that both
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Figure 3 HPTLC of mouse kidney GL-3, before () and after
() in vivo treatment with AGA-1.
Figure 4 Effect of a-Gal A on skin GL-3 levels in a-Gal A–
deficient mice. Values represent mean  1 SD for 4–10 skin patches
per mouse.
bands were GL-3, a kidney homogenate from an un-
treated a-Gal A–deficient mouse was incubated, at 37C
and pH 4.6, with 10,000 U of purified AGA-1, and the
neutral glycolipids were extracted and analyzed by
HPTLC. As shown in figure 3, both bands were hydro-
lyzed by the exogenous enzyme.
Similarly, clearance of the accumulated GL-3 in the
skin was dose dependent (fig. 4). Compared with the
mean level of skin GL-3 in untreated mice (∼1,990 ng/
mg; ), eight every-other-day doses of 0.3, 1.0, ornp 10
3.0 mg of enzyme/kg (followed by killing of the mice
24 h later) reduced the mean skin GL-3 level by ∼85%,
∼55%, and ∼60%, respectively. Five daily doses of 10
mg/kg (following by killing of the mice 24 h later) further
reduced skin GL-3 levels, to 450 ng/mg ( ), an av-np 4
erage clearance of ∼80%.
Depletion and Reaccumulation of Tissue and Plasma
GL-3: Dose Dependence
The rate of depletion and reaccumulation of tissueGL-
3 in a-Gal A–deficient mice was determined after a single
dose of 3 mg of AGA-1/kg (fig. 5). As expected, liver
GL-3 levels remained undetectable during the 4 wk of
study. Splenic and cardiac GL-3 levels were maximally
decreased at 3 wk, whereas reaccumulation of GL-3 was
evident in both tissues at 4 wk. It is noteworthy that the
plasma GL-3 decreased to nondetectable levels at 1 wk
and then increased over time, to ∼40% of pretreatment
levels, at 2.5–3 wk.
Since it appeared that the plasma GL-3 increased as
the tissue GL-3 reaccumulated, the plasma GL-3 levels
were determined before and at 24-h intervals after single
injections of 0.3, 1.0, 3.0, and 10 mg of AGA-1/kg. After
an initial increase in plasma GL-3 concentrations at 24
h postinjection (except for the dose of 10 mg/kg), dose-
dependent decreases in the levels of circulating GL-3
were observed (fig. 6). Not only the magnitude but the
rapidity and duration of the decrease depended on the
dose. For all doses, maximal decreases occurred ∼7 d
postinjection. The dose of 10 mg/kg reduced the plasma
GL-3 to wild-type levels, which were maintained on day
11 postinjection. After doses of 0.3, 1.0 and 3.0 mg/kg,
the levels of plasma GL-3 reaccumulated in a dose-de-
pendent manner, and the levels 11 d postinjection were
∼50%, ∼15%, and ∼5%, respectively. HPTLC analysis
confirmed that AGA-1 had an effect on depletion and
reaccumulation of plasma GL-3 (data not shown).
Ultrastructural Demonstration of Tissue GL-3
Clearance
Prior to treatment, the a-Gal A–deficient mice had
numerous lamellar osmophilic-dense membrane-bound
inclusions in the liver, spleen, heart, and kidneys (fig. 7,
a and b series). After four every-other-day doses of AGA-
1 (3 mg/kg), the number, size, and density of these in-
clusions were markedly decreased (fig. 7, c and d series).
It is noteworthy that the posttreatment liver sinusoids
were lined with numerous large empty-appearing, pre-
sumably fluid-filled vacuoles (fig. 7, 1c and 1d).
Discussion
Early pilot studies of enzyme-replacement therapy in Fa-
bry disease demonstrated that intravenously adminis-
tered a-Gal A could hydrolyze the accumulated circu-
lating GL-3 (Mapes et al. 1970; Brady et al. 1973;
Desnick et al. 1979; Bishop et al. 1981). These trials
also indicated that the highly sialylated enzyme purified
from human plasma was more effective in depleting the
accumulated circulating GL-3 than was the processed
enzyme purified from human splenic lysosomes (Desnick
et al. 1979; Bishop et al. 1981). Subsequent trials were
precluded because of the lack of sufficient human en-
zyme and of an animal model to assess the pharmaco-
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Figure 5 Effect of a-Gal A (3 mg/kg) on depletion and reac-
cumulation of GL-3 in tissues and plasma of a-Gal A–deficient mice.
Values represent the mean  1 SD for three mice.
Figure 6 Effect of a-Gal A dose on plasma GL-3 concentration
in a-Gal A–deficient mice. Values represent the mean 1 SD for three
to five mice.
kinetics and biodistribution of the administered enzyme
and the enzyme’s ability to hydrolize the accumulated
GL-3 in tissue sites of pathology. The recent availability
of a novel method to overexpress and selectively secrete
various recombinant human a-Gal A glycoforms (Ioan-
nou et al. 1992, 1998), the generation of an a-Gal
A–deficient mouse (Wang et al. 1996), and the devel-
opment of a rapid and sensitive ELISA for GL-3 (Zeidner
et al. 1999) permitted the systematic evaluation of four
a-Gal A glycoforms, providing the first preclinical in
vivo evidence that a-Gal A administration depletes the
accumulated GL-3 in the plasma and in the lysosomes
of pathogenic tissues.
Surprisingly, the four recombinant a-Gal A glyco-
forms, which varied in the number of sialic acid and
M6P residues, had similar pharmacokinetics and tissue
distributions. It was anticipated that the more highly
sialylated forms would circulate longer and would have
higher uptake by extrahepatic tissues. Although the
more highly sialylated—AGA-1 and AGA-3—glyco-
forms were retained in the circulation longer (fig. 2),
the biodistribution of all four glycoforms was remark-
ably similar, in that ∼95% of each was recovered in the
liver and the remainder of each was detected in the
spleen and kidneys (table 2). A 10-fold–increased dose
of the AGA-1 glycoform altered the biodistribution
slightly, since activity also was detected in the heart and
lungs. Even at the high dose (10 mg/kg), no enzymatic
activity was detectable in the brain, consistent with the
inability of the high-molecular-weight (∼110 kD) en-
zyme to cross the blood-brain barrier. Presumably, the
hepatic uptake was not influenced by the degree of sia-
lylation or retention in the circulation but was mediated
primarily by the mannose receptors for reticuloendothe-
lial uptake and by the M6P receptors for lysosomal
targeting (Jansen et al. 1991; Dini et al. 1992; Bijster-
bosch et al. 1996). Consistent with this notion is the
finding that the administration of mannans to block the
mannose receptors prior to enzyme injection prolonged
the circulatory T½ of AGA-1 (from ∼4 min to 160 min)
and markedly increased the kidneys’ uptake of the en-
zyme (from ∼1% to 10% of recovered activity 1 h post-
injection). Similar findings have been reported by others
(Fiddler et al. 1977; Achord et al. 1978; Rattazzi et al.
1980; Bijsterbosch et al. 1996). Thus, it is likely that
the mannose and M6P receptors are predominantly re-
sponsible for the biodistribution and lysosomal target-
ing of the exogenous a-Gal A glycoforms. It is note-
worthy that murine antibodies to the heterologous
human enzyme were not detected during these single-
or multiple-dose short-term studies. However, in sepa-
rate experiments, the immunogenicity of the human
AGA-1 glycoformwas assessed in mice by ELISA. Single
doses of 0.3 mg/kg mice), 1 mg/kg ( mice),(np 6 np 7
or 10 mg/kg ( mice) did not produce antibodiesnp 3
to human AGA-1 6 wk after administration. Eight in-
jections of 10 mg of AGA-1/kg produced anti–a-Gal A
antibodies in 3 of 10 mice at 6 wk. None of the anti-
bodies were neutralizing.
Since ∼95% of the recovered enzyme (i.e., ∼30% of
the dose) was in the liver, it is not surprising that most
of the accumulated hepatic GL-3 was cleared after a
single injection of the lowest dose, 0.3 mg/kg (table 4).
Figure 7 Representative electron micrographs of glutaraldehyde-fixed liver (row 1), heart (row 2), and kidneys (rows 3–5) of a-Gal
A–deficient mice, before (a and b series) and 7 d after (c and d series) enzyme treatment with 3 mg/kg every other day for four doses. Note
the presence (1a and 1b) and absence (1c and 1d) of osmophilic dense storage material in Kupffer cell lysosomes in liver sinusoids. In the heart,
the storage material was present in the lysosomes of cardiac pericytes and in the pericapillary histiocytes and fibroblasts (2a and 2b, arrows),
whereas these deposits were not observed posttreatment (2c and 2d). In the kidneys, numerous lysosomes (arrows) containing storage material
were present in the pericytes of capillaries (3a and 3b), in the cells lining the proximal convoluted tubules (4a and 4b), and in the apical
cytoplasm of the cells lining the distal convoluted tubules (5a and 5b). In contrast, the stored material was absent or markedly reduced in these
renal cells posttreatment (3c and 3d, 4c and 4d, and 5c and 5d, respectively). Ultrathin sections were stained with uranyl acetate and lead
citrate.
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Figure 8 Electron micrograph of a kidney tubule from an a-Gal A–deficient mouse. Osmophilic dense lipid bodies can be seen secreted
into the lumen of the tubule.
A 10-fold–higher dose (3 mg/kg) resulted in significant
clearance in the heart, spleen, and kidneys, indicating
that the amount of enzyme delivered to each tissue was
critical for depletion of the substrate. When enzyme
administration was increased to eight doses over 14 d,
the level of GL-3 was remarkably reduced, as a function
of dose, in all tissues analyzed (table 5 and fig. 4). Only
the accumulated renal GL-3 was not completely cleared,
even at the highest dose administered. Unlike humans
(Boyd and Lingwood 1989), male wild-type mice have
a testosterone-induced form of GL-3 (McCluer et al.
1981, 1983), which was one of the two GL-3 species
observed in approximately equal quantities in the a-Gal
A–deficient mice. The testosterone-induced GL-3 is se-
creted into the urine in multilammellar bodies, in both
normal (Gross et al. 1991) and a-Gal A–deficient mice
(fig. 8), and appears to be inaccessible to exogenously
administered a-Gal A.
The rate of reaccumulation of GL-3 after a single
enzyme dose of 3 mg/kg was assessed to indicate the
dose frequency that would maintain reduced GL-3 lev-
els. The accumulated hepatic GL-3 was rapidly cleared,
and it remained at undetectable levels for 4 wk,
whereas the splenic and cardiac GL-3 concentrations
were maximally decreased at 2 and 3 wk postinjection,
respectively, after which both began to reaccumulate
(fig. 6). These findings suggest that a biweekly dose of
a-Gal A could both deplete the accumulated GL-3 and
prevent its reaccumulation.
The biochemical demonstration of depletion of ac-
cumulated tissue GL-3 is consistent with the ultrastruc-
tural findings of absent, fewer, smaller, and/or less-dense
lysosomes in the tissues of treated mice (fig. 7). Mark-
edly decreased lysosomal glycolipid storage was ob-
served in the pericytes of vascular smooth-muscle cells
systemically, in fibroblasts and histiocytes of the heart,
in Kupffer cells, and in the ducts of the kidneys. The
finding of numerous translucent vacuoles lining the he-
patic sinusoids after enzyme administration suggests
that a-Gal A is readily endocytosed into endosomes, for
subsequent delivery to lysosomes containing the stored
substrate. These vacuoles were most prevalent in the
liver, consistent with the fact that ∼30% of dose was
delivered to the liver. Similar ultrastructural findings
have been observed in cultured rat hepatocytes after the
incubation of gold-labeled lactosylated albumin or in-
vertase (Dini et al. 1992). Thus, the hydrolysis of the
accumulated substrates, the prolonged activity in tis-
sues, and the morphological clearance of lysosomal de-
posits indicate that the exogenous a-Gal A was effec-
tively endocytosed and delivered to tissue lysosomes.
It is noteworthy that the depletion and reaccumula-
tion of plasma GL-3 also was dose dependent (fig. 6),
suggesting that the plasma GL-3 levels reflected the tis-
sue load. Since a-Gal A is not active at the neutral pH
of blood (Desnick et al. 1973), and since circulating
glycosphingolipids are carried by plasma lipoproteins
synthesized in hepatocytes (Attie et al. 1982; Chatterjee
and Kwiterovich 1984), it is likely that the decrease in
plasma GL-3 levels after enzyme administration results
from the clearance of stored tissue substrate. Thus, the
plasma GL-3 levels may provide an easily accessible
indicator of the tissue GL-3 load, as a way to monitor
dose effectiveness in patients with Fabry disease.
Table 4
GL-3 Concentrations in a-Gal A–Deficient Mice after a Single Dose of AGA-1
DOSE
(mg/kg)
LIVER SPLEEN HEART KIDNEYS
Mean GL-3 Con-
centration [Range]a
(ng/mg wet wt) % Untreated
Mean GL-3 Con-
centration [Range]a
(ng/mg wet wt) % Untreated
Mean GL-3 Con-
centration [Range]a
(ng/mg wet wt) % Untreated
Mean GL-3 Con-
centration [Range]a
(ng/mg wet wt) % Untreated
Untreated 377 [344–454] 100 2,790 [2,340–3,080] 100 196 [169–224] 100 1,100 [997–1,180] 100
.3 26 [12–48] 6.9 1,350 [1,400–1,440] 48.3 191 [42–327] 97.4 804 [756–845] 73.4
1.0 !1. 0 0 683 [676–694] 24.5 95 [32–158] 48.5 650 [650–765] 59.3
3.0 !1. 0 0 310 [294–320] 11.1 68 [24–106] 34.7 689 [643–726] 62.9
a In at least three mice, 7 d postinjection.
Table 5
Effect of Eight AGA-1 Doses on Tissue GL-3 Concentrations in a-Gal A–Deficient Mice
DOSE
(mg/kg)
LIVER HEART SPLEEN KIDNEYS
Mean GL-3
Concentrationa
(ng/mg wet wt) % Untreated
Mean GL-3
Concentrationa
(ng/mg wet wt) % Untreated
Mean GL-3
Concentrationa
(ng/mg wet wt) % Untreated
Mean GL-3
Concentrationa
(ng/mg wet wt) % Untreated
Untreated 420 100 197 100 1,190 100 1,030 100
.3 !1.0 0 64.8 33 897 76 670 65
1.0 !1.0 0 52.4 27 747 63 484 47
3.0 !1.0 0 13.6 7 596 50 448 43
10.0 !1.0 0 !1.0 0 … … 419 41
a In at least three mice injected every other day for eight doses and then killed 24 h later, on day 15.
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In summary, these animal studies provide the first
systematic in vivo evaluation of a-Gal A replacement
for Fabry disease. The findings demonstrate that a-Gal
A is delivered to the target sites of pathology in the
murine model of Fabry disease and that the clearance
of the accumulated GL-3 in tissues is dose dependent.
These results provide critical preclinical data for the
design of a-Gal A–replacement trials in patients with
Fabry disease (Eng et al. 2000a, 2000b; Schiffmann et
al. 2000a, Schiffmann et al. 2000b).
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